Repurposing selective serotonin reuptake inhibitors for severity of COVID-19: A population-based study.

ABSTRACT: The World Health Organization has proposed that a search be made for alternatives to vaccines for the prevention and treatment of COVID-19, with one such alternative being selective serotonin reuptake inhibitors (SSRIs). This study thus sought to assess: the impact of previous treatment with SSRI antidepressants on the severity of COVID-19 (risk of hospitalisation, admission to an intensive care unit [ICU], and mortality), its influence on susceptibility to SARS-CoV-2 and progression to severe COVID-19. We conducted a population-based multiple case-control study in a region in the north-west of Spain. Data were sourced from electronic health records. Adjusted odds ratios (aORs) and 95%CIs were calculated using multilevel logistic regression. We collected data from a total of 86,602 subject

SUBMITTER: Visos-Varela I 

PROVIDER: S-EPMC10070770 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature